|Podcasts|April 29, 2021

Episode 81: Cancer Research Amid COVID

Dr. Michele Cleary, CEO of the Mark Foundation for Cancer Research, discusses how the foundation has navigated COVID to help keep critical cancer research going throughout the pandemic.

Dr. Michele Cleary, CEO of the Mark Foundation for Cancer Research, talks about the challenges and silver linings of continuing cancer research during the pandemic.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.